<DOC>
	<DOCNO>NCT00558103</DOCNO>
	<brief_summary>The double blind part study conduct compare efficacy safety pazopanib combination lapatinib lapatinib alone subject inflammatory breast cancer whose tumor overexpress ErbB2 protein . There also Open-label pazopanib arm study design test whether pazopanib give alone lapatinib give alone would safe effective treat patient inflammatory breast cancer .</brief_summary>
	<brief_title>Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Inclusion criterion : Specific information regard warning , precaution , contraindication , adverse event , pertinent information investigational product may impact patient eligibility provide pazopanib IB lapatinib prescribe information ( lapatinib IB ) . For Cohort 1 study , eligible patient meet inclusion criterion outline original version protocol protocol amendment 1 . For Cohort 2 study , eligible patient must meet following criterion : Patients must evaluable Inflammatory Breast Cancer ( IBC ) substantiate follow prior randomization : History invasive breast cancer document biopsy accompany pathology report Current photographs* ( global view closeup view skin lesion ) submit screen demonstrate unequivocal evidence IBC determine either medical monitor alone consultation one study Principal Investigators . All patient must photography screening . Canfield Scientific Inc. provide centralize monitoring , track , collection patient ' photograph throughout study . Screening photograph must upload Canfield Scientific Inc website approve Canfield Scientific Inc , central photography vendor . The photograph , along complete Inflammatory Breast Cancer Skin Assessment Tool ( IBSAT ) , must review approved GSK patient randomize . Sites allow minimum 3 business day process . Sites submit quality photograph IBSATs regular basis receive exemption requirement future patient . Patients secondary IBC eligible . Measurable lesion ( cutaneous radiographic ) may field prior standard palliative radiation therapy ; however , must least 4 week period last radiation treatment baseline scan document disease status lesion measurable . If irradiate lesion site disease , document progression irradiate lesion require . Disease progression relapse follow treatment invasive breast cancer , must include chemotherapy regimen . In region trastuzumab available barrier access* , patient must receive prior trastuzumab addition chemotherapy order eligible . * ( Barriers access may include financial consideration . ) Unequivocal ErbB2 overexpressing breast cancer , define 3+ stain immunohistochemistry ( IHC ) , 2+ stain IHC conjunction ErbB2 gene amplification FISH/CISH , ErbB2 gene amplification FISH/CISH alone ( subject whose tumor block assess IHC ) . ErbB2 gene amplification define : &gt; six ( 6 ) ErbB2 gene copies/nucleus test system without internal control probe ErbB2/CEP 17 ratio 2.2 . Sites must submit copy laboratory report demonstrate unequivocal ErbB2 overexpression , test perform local laboratory , screen worksheet . Archived tumor must provide patient ErbB2 FISH test central laboratory . Patients remain study base local ErbB2 expression result . If archived tumor available , biopsy must obtain screen sent TMD Laboratories ErbB2 FISH test . Patients must provide write informed consent prior performance studyspecific procedures assessment , must willing comply treatment follow . Procedures conduct part patient 's routine clinical management ( e.g. , blood count , image study ) obtain prior signing inform consent may utilize screen baseline purpose provide procedure conduct specify protocol . Note : Informed consent may obtain prior protocolspecified screen window ( i.e . Day 14 Day 1 ) . Females age ≥ 18 year , except Tunisia . In Tunisia , patient must ≥ 20 year eligible study . Adequate organ function define : System ( Laboratory Values ) Hematologic : Absolute neutrophil count ( ANC ) ( ≥ 1.5 X 10^9/L ) Hemoglobin1 ( ≥9 g/dL ) Platelets ( ≥100 X 10^9/L ) International normalize ratio ( INR ) ( ≤ 1.2 X upper limit normal ( ULN ) ) Partial thromboplastin time ( PTT ) ( ≤1.2 X ULN ) Hepatic : Total bilirubin2 ( ≤ 1.5 X upper limit normal ( ULN ) ) AST ALT ( ≤ 2.5 X ULN ) Renal : Serum Creatinine ( ≤ 1.5 mg/dL ) Or , serum creatinine &gt; 1.5 mg/dL , Calculated creatinine clearance ( ≥50 mL/min ) Urine Protein Creatinine Ratio ( &lt; 1 ) Patients may transfusion within 7 day screen assessment . Exception : Patients elevate bilirubin level due Gilberts syndrome eligible . Cardiac ejection fraction within institutional range normal measure echocardiogram . MUGA scan accept case echocardiogram perform inconclusive MUGA scan accept standard . Patients known history uncontrolled symptomatic angina , arrhythmia , congestive heart failure eligible . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . A female eligible enter participate study : Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include female : A hysterectomy A bilateral oophorectomy ( ovariectomy ) A bilateral tubal ligation Is postmenopausal Patients use hormone replacement therapy ( HRT ) must experience total cessation menses ≥ 1 year great 45 year age , OR , questionable case , follicle stimulate hormone ( FSH ) value &gt; 40 mIU/mL estradiol value &lt; 40pg/mL ( &lt; 140 pmol/L ) . Patients must discontinue HRT prior study enrollment due potential inhibition CYP enzymes metabolize estrogen progestin ( See Section 8 ) . For form HRT , least 24 week must elapse cessation HRT determination menopausal status ; length interval depend type dosage HRT . If female patient determine postmenopausal , must use adequate contraception , define immediately . Childbearing potential , include female negative serum pregnancy test within 2 week prior first dose study treatment , preferably close first dose possible , used adequate contraception since pregnancy test agree use adequate contraception describe . GSK acceptable contraceptive method , use consistently accordance product label instruction physician , follow : An intrauterine device document failure rate le 1 % per year . Vasectomized partner sterile prior female patient 's entry sole sexual partner female . Complete abstinence sexual intercourse 14 day exposure investigational product , dose period , least 21 day last dose investigational product . Doublebarrier contraception ( condom spermicidal jelly , foam suppository , film ; diaphragm spermicide ; male condom diaphragm spermicide ) . Note : Oral contraceptive reliable due potential drug drug interaction . Female patient lactate discontinue nursing prior first dose investigational product refrain nursing throughout treatment period 14 day follow last dose investigational product . French patient : In France , patient eligible inclusion study either affiliate beneficiary social security category . Patients meet follow criterion must enrol study : Treatment 14 day prior randomization cancer therapy ( tumor embolization , chemotherapy , immunotherapy , biological therapy , hormonal therapy ) treatment mitomycin within 6 week prior randomization . Such treatment may resume begin study entry . Note : Patients receive LHRH analogue therapy prior study may continue receive LHRH analogue duration study participation . Bisphosphonates permit started prior Day 1 . Any ongoing toxicity prior anticancer therapy &gt; Grade 1 and/or progress severity ( exception alopecia ) . Prior lapatinib therapy Her2/ErbB2 target therapy ( except trastuzumab ) . Prior therapy antiVEGF antibody VEGF/VEGFR target therapy . Use investigational agent , include investigational anticancer agent , within 28 day 5 halflives , whichever longer , prior first dose investigational product . Use prohibit medication within timeframes list Section 8.1.3 History another malignancy . Note : Subjects another malignancy diseasefree 5 year , subject history completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma eligible . If subject previously breast cancer , must HER2+ either 3+ overexpression IHC unequivocal HER2 gene amplification FISH CISH . History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except individual previouslytreated CNS metastasis , asymptomatic , requirement steroid antiseizure medication 2 month prior first dose study drug . Screening CNS image study ( compute tomography [ CT ] magnetic resonance image [ MRI ] ) require clinically indicated subject history CNS metastases . Clinically significant gastrointestinal abnormality may increase risk GI bleed include , limited : Active peptic ulcer disease Known intraluminal metastatic lesion/s suspect bleed Inflammatory bowel disease Ulcerative colitis , gastrointestinal condition increase risk perforation History abdominal fistula , gastrointestinal perforation , intra abdominal abscess within 28 day prior begin study treatment . Clinically significant gastrointestinal abnormality may affect absorption investigational product include , limited : Malabsorption syndrome Major resection stomach small bowel . Presence uncontrolled infection . Prolongation correct QT interval ( QTc ) &gt; 480 msec . History one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting Myocardial infarction Unstable angina Arterial thrombosis Symptomatic peripheral vascular disease Class III IV congestive heart failure , define New York Heart Association ( NYHA ) ( see Section 15.9 Appendix 9 description ) . Poorly control hypertension [ define systolic blood pressure ( SBP ) ≥140mmHg diastolic blood pressure ( DBP ) ≥ 90mmHg ] . Note : Initiation adjustment antihypertensive medication ( ) permit screening period , order control patient 's BP prior randomization . Blood pressure must reassess two occasion separate minimum 1 hour . The mean SBP / DBP value blood pressure assessment must &lt; 140/90mmHg order patient eligible study . See Section 6.2 Section 6.4.2 detail blood pressure control reassessment prior study enrollment . History cerebrovascular accident , include TIA , pulmonary embolism deep venous thrombosis ( DVT ) . Prior major surgery trauma within 28 day prior first dose investigational product and/or presence nonhealing wound , fracture , ulcer ( ulcer due inflammatory breast cancer ) . Evidence active bleeding bleed diathesis . Hemoptysis within 6 week prior first dose investigational product . Known endobronchial lesion involvement large pulmonary vessel tumor . Any serious and/or unstable preexist medical , psychiatric , condition could interfere patient 's safety , provision inform consent , compliance study procedure . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate pazopanib lapatinib . Have current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>GW572016</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>RECIST</keyword>
	<keyword>Inflammatory Breast Cancer</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>ErbB2</keyword>
	<keyword>Cutaneous Disease</keyword>
	<keyword>Tykerb</keyword>
	<keyword>Inflammatory</keyword>
	<keyword>Skin</keyword>
	<keyword>Her2</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>GW786034</keyword>
</DOC>